Skip to main content
. 2020 Jun 3;12(6):1459. doi: 10.3390/cancers12061459

Figure 5.

Figure 5

Functional role in SERPINB11 in ovarian cancer treated with eupatilin. (A) Dose-dependent effects of eupatilin on SERPINB11 mRNA expression levels in ovarian cancer cells were determined by quantitative RT-PCR analysis. (B) Expression levels of SERPINB11 and apoptosis-related proteins according to eupatilin dosage in ES2 and OV90 cells. (C) Expression of SERPINB11 protein was evaluated with each pharmacological inhibitor in eupatilin-treated ovarian cancer cells. (D) The mRNA expression of SERPINB11 according to the separate or combined use of eupatilin, cisplatin, and paclitaxel in ES2 and OV90 cells. (E) The synergistic inhibition of cell proliferation in response to the combination of eupatilin with cisplatin or paclitaxel in ES2 and OV90 cells. (F) The synergistic induction of cell death in response to the combination of eupatilin with cisplatin or paclitaxel in ES2 and OV90 cells. The experiments were performed in triplicate. Data represent the mean ± standard deviation, and asterisks indicate that the effect of treatment was statistically significant (* p < 0.05, ** p < 0.01, and *** p < 0.001). Lowercase letters indicate statistically significant (p < 0.05) effects of treatments: a, compared with eupatilin alone; b, compared with cisplatin alone; and c, compared with paclitaxel alone. Detailed information about the western blot can be found in Figure S6.